X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs AUROBINDO PHARMA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH AUROBINDO PHARMA PANACEA BIOTECH/
AUROBINDO PHARMA
 
P/E (TTM) x 170.2 14.0 1,214.0% View Chart
P/BV x 3.8 3.6 105.0% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 PANACEA BIOTECH   AUROBINDO PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
AUROBINDO PHARMA
Mar-17
PANACEA BIOTECH/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs149895 16.6%   
Low Rs82622 13.2%   
Sales per share (Unadj.) Rs84.1254.6 33.1%  
Earnings per share (Unadj.) Rs-18.339.3 -46.6%  
Cash flow per share (Unadj.) Rs-6.746.6 -14.4%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs83.7160.0 52.3%  
Shares outstanding (eoy) m61.25585.88 10.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.43.0 46.1%   
Avg P/E ratio x-6.319.3 -32.7%  
P/CF ratio (eoy) x-17.216.3 -105.9%  
Price / Book Value ratio x1.44.7 29.1%  
Dividend payout %06.4 0.0%   
Avg Mkt Cap Rs m7,074444,390 1.6%   
No. of employees `0002.814.0 19.7%   
Total wages/salary Rs m1,44917,678 8.2%   
Avg. sales/employee Rs Th1,874.110,667.8 17.6%   
Avg. wages/employee Rs Th527.01,264.3 41.7%   
Avg. net profit/employee Rs Th-407.71,645.8 -24.8%   
INCOME DATA
Net Sales Rs m5,154149,157 3.5%  
Other income Rs m1001,159 8.6%   
Total revenues Rs m5,254150,316 3.5%   
Gross profit Rs m-76634,343 -2.2%  
Depreciation Rs m7114,276 16.6%   
Interest Rs m1,503667 225.3%   
Profit before tax Rs m-2,88130,558 -9.4%   
Minority Interest Rs m1150 21.5%   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m177,597 0.2%   
Profit after tax Rs m-1,12123,012 -4.9%  
Gross profit margin %-14.923.0 -64.6%  
Effective tax rate %-0.624.9 -2.3%   
Net profit margin %-21.815.4 -141.0%  
BALANCE SHEET DATA
Current assets Rs m3,81092,062 4.1%   
Current liabilities Rs m8,36566,223 12.6%   
Net working cap to sales %-88.417.3 -510.2%  
Current ratio x0.51.4 32.8%  
Inventory Days Days156106 146.9%  
Debtors Days Days6768 99.4%  
Net fixed assets Rs m14,48062,919 23.0%   
Share capital Rs m61586 10.5%   
"Free" reserves Rs m90393,133 1.0%   
Net worth Rs m5,12793,719 5.5%   
Long term debt Rs m5,8321,814 321.5%   
Total assets Rs m19,433162,494 12.0%  
Interest coverage x-0.946.8 -2.0%   
Debt to equity ratio x1.10 5,876.3%  
Sales to assets ratio x0.30.9 28.9%   
Return on assets %2.014.6 13.5%  
Return on equity %-21.924.6 -89.1%  
Return on capital %3.632.7 11.1%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Exports (fob) Rs m1,264NA-   
Imports (cif) Rs m525NA-   
Fx inflow Rs m1,53975,838 2.0%   
Fx outflow Rs m94230,224 3.1%   
Net fx Rs m59745,613 1.3%   
CASH FLOW
From Operations Rs m59932,786 1.8%  
From Investments Rs m-438-17,870 2.5%  
From Financial Activity Rs m-303-19,153 1.6%  
Net Cashflow Rs m-141-4,239 3.3%  

Share Holding

Indian Promoters % 74.5 54.1 137.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 8.0 7.5%  
FIIs % 1.3 27.7 4.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 10.2 231.4%  
Shareholders   10,259 69,601 14.7%  
Pledged promoter(s) holding % 35.1 8.6 409.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   PLETHICO PHARMA  DIVIS LABORATORIES  FULFORD INDIA  NATCO PHARMA  AJANTA PHARMA  

Compare PANACEA BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Down Around 1%; Telecom & Metal Stocks Decline(01:30 pm)

Indian share markets are trading in the red presently. Sectoral indices are trading in the red with stocks in the telecom sector and metal sector witnessing maximum selling pressure.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Feb 19, 2018 02:03 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS